Wordt geladen...
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(−2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year surv...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2005
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2361887/ https://ncbi.nlm.nih.gov/pubmed/15700038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602394 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|